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Construct design, production, 
and characterization of Plasmodium falciparum 
48/45 R0.6C subunit protein produced 
in Lactococcus lactis as candidate vaccine
Susheel K. Singh1,2,3, Will Roeffen4, Ulrik H. Mistarz5, Bishwanath Kumar Chourasia1,2,3, Fen Yang5, 
Kasper D. Rand5, Robert W. Sauerwein4 and Michael Theisen1,2,3*
Abstract 
Background: The sexual stages of Plasmodium falciparum are responsible for the spread of the parasite in malaria 
endemic areas. The cysteine-rich Pfs48/45 protein, exposed on the surface of sexual stages, is one of the most 
advanced antigens for inclusion into a vaccine that will block transmission. However, clinical Pfs48/45 sub-unit vac-
cine development has been hampered by the inability to produce high yields of recombinant protein as the native 
structure is required for the induction of functional transmission-blocking (TB) antibodies. We have investigated a 
downstream purification process of a sub-unit (R0.6C) fragment representing the C-terminal 6-Cys domain of Pfs48/45 
(6C) genetically fused to the R0 region (R0) of asexual stage Glutamate Rich Protein expressed in Lactococcus lactis.
Results: A series of R0.6C fusion proteins containing features, which aim to increase expression levels or to facilitate 
protein purification, were evaluated at small scale. None of these modifications affected the overall yield of recombi-
nant protein. Consequently, R0.6C with a C-terminal his tag was used for upstream and downstream process devel-
opment. A simple work-flow was developed consisting of batch fermentation followed by two purification steps. As 
such, the recombinant protein was purified to homogeneity. The composition of the final product was verified by 
HPLC, mass spectrometry, SDS-PAGE and Western blotting with conformation dependent antibodies against Pfs48/45. 
The recombinant protein induced high levels of functional TB antibodies in rats.
Conclusions: The established production and purification process of the R0.6C fusion protein provide a strong basis 
for further clinical development of this candidate transmission blocking malaria vaccine.
Keywords: Plasmodium falciparum, Malaria, Transmission blocking, Pfs48/45, Batch fermentation and Lactococcus 
lactis
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Background
The transmission of Plasmodium falciparum malaria from 
one person to another requires the production of male 
and female gametocytes in the human host that can be 
taken up by blood-feeding mosquitoes. Recent studies have 
indicated that a large proportion of individuals in malaria 
endemic areas carry gametocytes and may contribute to 
malaria transmission [1]. Control strategies that confer pro-
longed protection including vaccines, are therefore needed 
to effectively block malaria transmission at the popula-
tion level [2]. P. falciparum Pfs48/45 is one of the leading 
transmission blocking vaccine (TBV) candidates that has 
entered the pipeline of clinical development (for a review 
see [3]). This protein is relatively cysteine-rich with multi-
ple disulfide bonds that result in antibody epitopes which 
are dependent on properly folded tertiary structures rather 
than linear amino acid sequences. Functional in  vitro 
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studies have identified the C-terminal portion of Pfs48/45 
(6C) containing three disulfide bonds as major target of 
transmission blocking (TB) antibodies [4]. This Pfs48/45 
region is targeted by a monoclonal antibody (mAb) 
mAb45.1 which promotes strong TB activity in the stand-
ard membrane feeding assay (SMFA), the gold standard for 
assessing transmission blockade ex vivo [5–8].
The production of Pfs48/45 in bacterial and eukaryotic 
expression systems has been problematic due to insuffi-
cient protein folding capabilities of these systems. Proper 
folding of cysteine-rich Pfs48/45 depends on correct for-
mation of disulfide bridges. Since eukaryotic cells possess 
a sophisticated machinery for disulfide bond formation, 
recombinant Pfs48/45 has been produced in a range of 
Baculovirus (Spodoptera frugiperda Sf9) cells [9], Vaccinia 
virus [10], Saccharomyces cerevisiae [11], and Pichia pas-
toris [11], Chlamydomonas reinhardtii [12], and Nicotiana 
benthamiana [13]. However, protein yields were rather low 
and in those cases where expression was successful, there 
was limited reactivity with mAbs against conformational 
TB epitopes suggesting misfolding. The bacterial Lacto-
coccus lactis expression system represents a significant 
advancement in the production of recombinant Pfs48/45 
[14, 15]. L. lactis cell factories generally recognized as safe 
(GRAS status) are well suited for the production of heter-
ologous proteins and used for a wealth of food applications. 
In the recent years, L. lactis has also been used in modern 
biotechnology within the fields of mucosal delivery [16] 
generation of self-adjuvanting bacterium-like particles [17] 
and recombinant proteins (reviewed in [18]. L. lactis do not 
produce endotoxins or extracellular proteases. Moreover, 
gene expression can be controlled by a set of tightly regu-
lated promoters in a simple and scalable fermentation pro-
cess from a few ml up to thousands of liters. Recombinant 
proteins can be secreted into the culture medium in the 
absence of spore formation which clearly facilitates down-
stream processing. Accordingly, L. lactis has been used for 
the manufacturing of the GMZ2 malaria vaccine candidate 
[19–22].
To advance development of a protein-vaccine based 
on Pfs48/45, we established a manufacturing process for 
R0.6C in L. lactis. The product was characterized by mass 
spectrometry (MS)-based and by HPLC-based methods 
and tested for functional immunogenicity in rats. The 
specificity of induced antibodies was assessed by ELISA, 
and functional capacity for transmission blockade in the 
standard membrane-feeding assay (SMFA).
Results
Molecular design and expression of chimeric 
GLURP‑Pfs48/45 fusion proteins
We designed a set of fusion proteins (Fig. 1a) consisting of 
the Pfs48/45 6-Cys domain to address whether expression 
levels of secreted R0.6C was affected by: (1) codon optimi-
zation, (2) different signal peptides, and (3) the presence 
and/or position of a range of affinity-tags. All constructs 
were transformed into L. lactis MG1363 and grown in 
5 ml of LAB medium at 30 °C without shaking. Firstly, the 
codon optimized construct generated the same amount 
of recombinant R0.6C fusion protein as did the non-opti-
mized construct (Fig.  1b, compare lanes 1 and 2). Sec-
ondly, we found that protein yields were similar between 
constructs with and without a His-tag (Fig. 1b, compare 
lanes 1 and 3), suggesting that the His-tag per see does not 
affect production yields of R0.6C. Thirdly, fusion proteins 
containing tags that can be used for various conjugation 
strategies including the SpyTag-spyCatcher technology 
[23, 24] and Streptavidin-mSA mediated conjugation to 
bacterial outer membrane vesicles [25] were explored. 
The addition of these tags to the N- or C-terminal end 
of R0.6C did not affect over all expression levels (Fig. 1b, 
lanes 5, 6, and 7). Finally, we showed that a native USP45 
signal peptide derived from an abundantly secreted L. lac-
tis protein did not increase protein yields in culture super-
natants (Fig. 1b, lanes 1 and 8).
Production of recombinant R0.6C in bioreactor
Since all constructs tested gave similar yields, we choose 
R0.6C with a C-terminal His-tag (Fig.  1a, construct no. 
1) for optimization of fermentation in lab-scale biore-
actors. The generation of R0.6C showed a substantial 
accumulation in the culture medium at 10–15  h post 
inoculation (Fig. 2a). Recombinant R0.6C was produced as 
an intact fusion protein as indicated by Coomassie stain-
ing (Fig.  2b upper panel) and immune blotting with an 
antibody against the C-terminal his-tag (Fig.  2b, middle 
panel). The secreted protein was properly folded as indi-
cated by immune blotting with the conformation depend-
ent mAb45.1 (Fig. 2b lower panel). Subsequently, a robust 
workflow for production was developed by growing L. 
lactis MG1363 expressing R0.6C in a 1  l stirred bioreac-
tor for 15 h at 30 °C (Fig. 3a). The non-oxidative fermenta-
tion resulted in rapid acidification due to the production 
of lactate. Acidification eventually inhibits cell growth but 
also induces protein expression by activating the P170 
promoter [18]. In order to optimize both cell growth and 
promoter activity, the fermenter was equipped with a pH 
electrode to monitor and control pH by addition of 2  M 
NaOH. The culture medium was also supplemented with 
5 mM cysteine and 0.5 mM cystine which, together with 
the micro-aerobic milieu, is essential for high yield pro-
duction of disulfide-bonded recombinant protein.
Purification of recombinant R0.6C
Supernatants were concentrated and buffer exchanged 
for phosphate buffered saline (PBS) pH 7.4 supplemented 
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with 15  mM imidazole. R0.6C was captured on a His-
Trap HP column and bound protein was eluted with a 
linear imidazole gradient (Fig.  3b). Fractions containing 
recombinant R0.6C were analyzed by SDS-PAGE and by 
mAb45.1 sandwich ELISA (Fig.  3b). Fractions contain-
ing high concentration of immune reactive protein were 
pooled and loaded on an anion ion-exchange chroma-
tography column, to separate protein species with native 
and non-native disulfide bonds (Fig.  3c). Fractions (P1) 
containing mAb45.1 reactive monomer were pooled with 
a major band of monomeric protein strongly reactive to 
mAb45.1 (Fig.  3d). This R0.6C fraction contained  >80% 
properly folded Pfs48/45 relative to immune purified ref-
erence material (Fig. 3e and Additional file 1). The same 
work-flow for R0.6C constructs tagged with SpyTag, 
SpyCatcher, and mSA at their N-terminal ends resulted 
in similar yields of properly folded R0.6C.
Mass spectrometry analysis of R0.6C
The mass of non-reduced and reduced full-length R0.6C 
was 71325.4 and 71331.3  Da as determined by LC–MS 
respectively (Additional file 2a, b). This molecular weight 
corresponds well to the predicted value of 71331.01  Da 
assuming that the fusion protein contains the vector-
encoded amino acid residues A-E-R-S at the N-terminal 
end and a 6xHis-tag at the C-terminal end. Reduction 
of R0.6C resulted in a shift in the measured mass of 
the intact protein by approximately 6  Da, consistent 
with the presence of 3 disulfide bonds. The correct pri-
mary structure of R0.6C was further verified through 
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Fig. 1 Constructs for expression of R0.6C in L. lactis. a Schematic representation of Pfs48/45 and the R0.6C constructs: 1 C-terminal 6xHis-tag, 2 
codon optimized genes (hiligheted with color shades), 3 no tag, 4 N-terminal Spytag, 5 N-termianl SpyCatcher, 6 N-terminal mSA, 7 C-terminal mSA, 
8 USP45 signal peptide. The protein yield of each construct was determined by densitometry scanning of the Coomassie stained SDS-PAGE gel 
shown below. b Upper panel Coomassie blue-stained 4–12.5% polyacrylamide gel for the constructs shown in a. Lower panel an immunoblot analy-
sis of the same gel shown in the upper panel using mAb45.1
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MS/MS sequencing of 39 tryptic peptides derived 
from reduced R0.6C (Additional file  2c). These pep-
tides cover 85% of the protein confirming that the puri-
fied R0.6C fusion protein was intact with the predicted 
amino acid residues corresponding to a full-length 
 GLURP27–500–Pfs48/45291–428 fusion protein.
The disulfide connectivity of R0.6C was character-
ized by analyzing tryptic peptides by LC–MS/MS. Four 
peptides were not found in non-reduced R0.6C sample, 
indicating their involvement in cross-linking, whereas, 
two peptides were exclusively present in non-reduced 
R0.6C, referred to as XL-peptides I and II (Fig.  4a, b, 
respectively). The identity of these cross-linked peptides 
was established by manual inspection of masses of pep-
tide precursors and the corresponding fragment ions 
(Fig.  4d for peptide I). In XL-peptide I, C492 formed a 
disulfide bond with C521. In XL-peptide II, C604 was 
disulfide bonded to C546 or C538, whereas C606 formed 
a disulfide bond with the other cysteine residue. Due to 
the close proximity of C604 and C606 it was only possi-
ble to resolve the disulfide connectivity to either of the 
two cysteine residues. Several control peptides without 
cysteine residues were monitored simultaneously with 
an example shown in (Fig. 4d). A diagram of the disulfide 
connectivity of the correctly folded Pfs48/45-6C region is 
shown in (Fig. 4e).
Size‑exclusion and reversed‑phase HPLC analysis 
of purified R0.6C
A Pfs48/45-based vaccine antigen should consist of 
properly folded monomer. The final R0.6C batch elutes 
as a single peak at 42.5  min by analytical size exclusion 
chromatography (SEC), representing the active monomer 
state (Fig. 5a). Subsequent reversed-phase chromatogra-
phy analysis showed a main peak with a retention time 
of 17.0 min and a smaller peak at approximately 16.5 min 
(Fig. 5b). The latter was absent in reference material con-
taining immune-purified R0.6C (data not shown) sug-
gesting that this peak corresponds to host cell proteins or 
a minor fraction of product-related impurities. The over-
all purity of R0.6C as determined by RP-HPLC was 87%.
Stability of recombinant R0.6C
Finally, we assessed the chemical and physical stability of 
the recombinant protein for 30 days at 4 °C. There was no 
appreciable degradation at any time-point when analyzed 
by SDS-PAGE, immunoblotting with mAb45.1 (Addi-
tional file  3). The bioactivity of the protein was main-
tained throughout the experiment as determined by the 
sandwich-ELISA (Additional file 3).
Immunogenicity of recombinant R0.6C
To ascertain that R0.6C elicit adequate levels of game-
tocyte-specific antibodies with the capacity to inhibit 
parasite fertilization, Wistar rats (N  =  8) were immu-
nized 3 times at 3-week intervals with increasing doses 
(2.5, 10, and 25  μg) of R0.6C inducing similar levels of 
vaccine-specific (Fig. 6a), epitope I-specific (Fig. 6b), and 
6C-specific (Fig. 6c) antibodies. There was a strong corre-
lation between 6C- and epitope I specific antibody levels 
(Fig. 6d) suggesting that epitope I is the main epitope in 
the 6-Cys domain of Pfs48/45. Collectively, these results 
demonstrate that R0.6C gives an adequate presentation of 
conformational epitope(s) in Pfs48/45. Serum pools from 
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Fig. 2 Time course analysis of the expression of R0.6C in L. lactis. 
a Optical density measurements at 600 nm from 0 to 15 h during 
expression of R0.6C. b Samples collected from 9 to 15 h were ana-
lyzed. For Coomassie (20 µl) and WB (10 µl) samples without a reduc-
ing agent were loaded on SDS-PAGE gel. Upper panel Coomassie 
blue-stained 4–12.5% polyacrylamide gel. Middle panel an WB analysis 
of the same gel shown in the upper panel using anti-His antibody. 
Lower panel an immune blot analysis of the same gel shown in the 
upper panel using mAb45.1
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each dosing group were tested for functional activity in 
the SMFA showing >99% TB activity at a 1/9 dilution.
Discussion
Production of recombinant protein is important for sub-
unit vaccine development. Since there is no single uni-
versal host, which is perfect for production of all desired 
recombinant proteins, the selection of the right expres-
sion system is pivotal for development of a manufactur-
ing process. The production host is not only important 
for the correct protein folding (protective antibodies 
often target conformational epitopes) but also process 
economics are key to keeping the price of the vaccine 
as low as possible, especially for vaccines targeting low-
income countries.
From a manufacturing perspective, the major challenge 
with recombinant Pfs48/45 is production of correctly 
folded protein with sufficient yield (reviewed in [3]). One 
way to increase the amount of properly folded protein 
has been to produce Pfs48/45 in the L. lactis expression 
system genetically fused to the GLURP-R0 region [14, 
15]. The efficient expression of disulfide-bonded pro-
tein in L. lactis was unexpected as this organism is low 
in its cysteine content and lacking known disulfide bond 
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Fig. 3 Expression and purification of R0.6C. a Schematic representation of expression and purification R0.6C fusion protein. Elution profiles of 
R0.6C on the b HisTrap HP and c HiTrap Q-HP-columns. Red line denotes UV absorbance (A280) and the black line denote antibody reactivity in the 
mAb45.1 sandwich ELISA. Selected fractions (5 µl) were analyzed on 4–12.5% polyacrylamide gels shown below the chromatograms. Protein was 
loaded without a reducing agent. The sizes (kDa) of the molecular mass markers are indicated. d Analysis of R0.6C. Left panel Coomassie blue-
stained 4–12.5% polyacrylamide gel; 1 Supernatant, 2 HisTrap HP column and 3 HiTrap Q HP column purified R0.6C. Right panel an immune blot 
analysis of the same gel shown in the left panel using mAb45.1. Protein was loaded in each lane with (+) or without (−) DTT (10 mM). e Sandwich 
ELISA of conventionally (CP) and Immune (IP) purified R0.6C fusion proteins. Antigens were captured with mAb45.1 and detected with anti-His-HRP. 
X-axis is shown on a logarithmic scale
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Fig. 4 Mapping of disulphide-bonds in the Pfs48/45-6C region of R0.6C. R0.6C with and without reduction was digested with the protease trypsin 
prior to LC–MS/MS analysis. Two crosslinked peptides were identified and corresponding mass spectra of each peptide is shown in a and b with 
mass spectra corresponding to the non-reduced sample in black and the corresponding mass spectra from the reduced sample in blue. The pro-
posed disulfide connectivity is indicated (green dashed lines) based on the extensive MS/MS fragmentation of each peptide (solid black lines). Several 
control peptides without cysteine residues were analyzed alongside to confirm equal sample load in each analysis, and spectra for one of these in 
shown c. Annotated MS/MS spectra of the peptide from a is shown in d. Schematic of the identified disulfide connectivity of Pfs48/45-6C in R0.6C 
is shown in e. The disulfide bonds that have been verified by LC–MS/MS is indicated by a solid black line and disulfide bonds indicated with dashed 
green lines is one of two possibilities
Fig. 5 Size exclusion and reversed-phase HPLC analysis of purified R0.6C. a Size exclusion chromatography was performed under native conditions 
in a phosphate buffer pH 6.7, to determine the amount of monomer in the sample. The peak corresponding to the monomer is indicated with the 
integrated area of the peak written above. b Reversed-phase HPLC–UV chromatograms recorded following analysis of purified protein batches. The 
peak at 17 min corresponds to monomeric R0.6C antigen
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forming enzymes [26]. Thus, disulfide bond formation of 
recombinant Pfs48/45 most likely occurs spontaneously 
after secretion and is not only dependent on the primary 
structure but also on environmental factors that deter-
mine cysteine oxidation. By carefully optimizing the ratio 
of different redox couples in the fermentation broth, we 
have identified conditions, which render the extracel-
lular milieu more oxidizing allowing formation of struc-
tural disulfide bonds in the Pfs48/45-6C domain of the 
fusion protein. These conditions seem to favor the forma-
tion of intramolecular disulfide bonds as secreted R0.6C 
was mainly present in the monomer state. However, the 
finding that crude R0.6C shows reduced reactivity with 
mAb45.1 compared to the reference material consisting 
of mAb45.1 immune-purified R0.6C [14] suggests that 
the monomer fraction contains a mixture of conformers 
with native and non-native cysteine connectivity. A work-
flow has therefore been developed using batch fermenta-
tion in lab-scale stirred bioreactor to produce discreet 
batches of recombinant R0.6C purified by a simple 2-step 
purification process. The first step captures the recombi-
nant protein from the culture supernatant and the second 
step aims to separate correctly folded and misfolded pro-
tein species. The SEC–HPLC analysis demonstrates that 
the final batch of R0.6C mainly contains monomers with 
all six cysteine residues in the oxidized state as shown 
by mass spectrometry analysis. The established disulfide 
connectivity of R0.6C is in excellent agreement with the 
disulfide bond connectivity of another recombinant pro-
tein containing the Pfs48/45-10C region (Mistarz et  al., 
unpublished). The purity of the R0.6C batch is 87% as 
determined by RP-HPLC. Impurities in the final R0.6C 
batch are likely, at least in part, product-related consist-
ing of misfolded protein species or degradation products.
Although the final yield of purified recombinant R0.6C 
is almost 25 mg per L culture broth, we suggest that fur-
ther improvements are possible. Such improvements 
may include procedures to increase the biomass through 
systems where lactate is removed from the culture broth 
during fermentation using for example the REED™ 
(Reverse Electro-Enhanced Dialysis) technology [18]. 
Alternatively, product yield may be increased through 
adjusting the fermentation process, which is very easy to 
scale up to 200–1000 L since there is no requirement for 
Fig. 6 Immunogenicity of purified R0.6C. Rats were immunized with increasing doses (2.5, 10, and 25 µg) of purified R0.6C. Levels of specific 
antibodies were measured in the a R0.6C-ELISA, b mAb45.1 competitive ELISA, and c Pfs48/45-6C-ELISA. e Relationship between antibody levels 
determined in the 6C-ELISA and the 45.1 competition ELISA. Antibody titres are expressed as EC50 values. The line represents the median value. P 
values are based on the Mann–Whitney rank sum test
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oxygen and heavy stirring during fermentation. Finally, 
product yields can be increased through performing 
multiple fermentations that can be pooled before down-
stream purification.
Previously we have investigated the immunogenicity of 
Pfs48/45-based vaccine candidates using immune puri-
fied protein [14, 15, 27]. Here, we showed that Pfs48/45 
fusion protein purified by conventional chromatographic 
procedures together with Montanide ISA 720 VG elic-
its TB antibodies at the lowest dose of 2.5  µg. Previ-
ously, doses below 4.7  µg failed to elicit TB antibodies 
when adjuvanted in Alhydrogel [14]. Improved formula-
tions may contain immune modulators [28, 29] or may 
be based on novel delivery systems including virus like 
particles (VLP). This concept has been demonstrated 
recently for another TBV candidate, Pfs25, which was 
covalently coupled to VLPs [23, 24]. In this context, it 
is clearly important that the L. lactis expression system 
is able to accommodate a range of affinity tags added to 
either end of the recombinant protein.
In conclusion, we have demonstrated that L. lactis 
microbial factories are highly suited for the production 
of Pfs48/45. A manufacturing process for soluble and 
correctly folded R0.6C was developed and the resulting 
vaccine antigen induces high levels of functional anti-
bodies. The high yield of correctly folded protein and the 
straightforward production process offers the possibility 
to investigate the vaccine potential of Pfs48/45 in human 
clinical trials.
Methods
Preparation of constructs
All the constructs are based on the L. lactis pSS1 plas-
mid vector [14]. The R0.6C construct with a C-terminal 
His tag has been described [14]. Non-tagged R0.6C was 
generated through PCR with forward primer (5′-GAAT 
GGA TCC TAC AAG TGA GAA TAG AAA TAA ACG) 
and reverse primer (5′-GAAT AGA TCT TTA TGC 
TGA ATC TAT AGT AAC TGT CAT ATA AGC) using 
R0.6C.6H gene as template. Codon optimized R0.6C.6H 
and N-terminal SpyCatcher and SpyTag [30] containing 
BamHI-BglII was synthesized by  (GeneArt® Life Tech-
nologies, Germany) and inserted into pSS1. For con-
struction of chimeric N-terminal (mSA-R0.6C.6H) or 
C-terminal (R0.6C-mSA.6H) R0.6C, a synthetic DNA 
fragment encoding the monomeric Streptavidin (mSA) 
(GeneBank: 4JNJ_A) with a small Gly–Gly-Ser linker 
was synthesized by  (GeneArt® Life Technologies) and 
cloned into R0.6C.6H. The USP45-R0.6C.6H construct 
was generated by replacing the mutD310 signal peptide 
in pSS1 with the USP45 signal peptide [31] synthesized 
by  (GeneArt® Life Technologies) and cloned into R0.6C. 
All the constructs were verified by sequencing and 
subsequently transformed into L. lactis MG1363 by elec-
troporation as described [32].
Screening, fermentation and protein purification
L. lactis MG1363, containing R0.6C constructs was 
grown overnight at 30 °C in 5 ml LAB medium [15] sup-
plemented with 4% glycerol–phosphate, 5% glucose and 
5  µg/ml erythromycin. Culture supernatants were clari-
fied by centrifugation at 9000g for 20 min and analysis of 
all the constructs was performed by Coomassie stained 
SDS-PAGE gel and Western blotting with mAb45.1 
against conformational epitope I. Fermentation of L. lac-
tis MG1363/R0.6C.6H was performed in a 1  l lab scale 
bioreactor at 30 °C with gentle stirring (150 rpm). For the 
time-course experiment 10  ml samples were withdrawn 
and used for analysis. Optical density at 600 nm (OD600) 
was used to assess cell density. Cell-free culture-filtrates 
were concentrated tenfold and buffer exchanged into 
phosphate buffered saline (PBS) pH 7.4 supplemented 
with 15  mM imidazole) using a QuixStand Benchtop 
system (Hollow fiber cartridge with cutoff at 50,000 Da, 
surface area 650  cm2, GE Healthcare, Sweden) followed 
by filtration through a Durapore filter (PVDF, 0.22  µm, 
Millipore) and applied to a 5  ml HisTrap HP column 
(GE Healthcare, Sweden). Bound protein was step gradi-
ent eluted with 500 mM imidazole in tris buffer pH 8.0 
(55 mM tris, 21 mM NaCl) at a flow rate of 4 ml/min and 
fractions containing the desired protein were applied to 
a 5  ml HiTrap Q HP column (GE Healthcare, Sweden). 
Bound protein was eluted through step gradient elution 
in tris buffer pH 8.0 (55  mM tris, 1  M NaCl) and frac-
tions containing monomers with the highest amount of 
mAb45.1-reactive protein were concentrated by a VIVA 
spin column 30 kDa cutoff (GE Healthcare, Sweden), and 
kept in 55 mM tris, 300 mM NaCl, 0.025% Tween 80 and 
1 mM EDTA, pH 8.0 at −80 °C until use. Immune puri-
fication of R0.6C was performed as described earlier [14, 
15]. Analysis of all the fractions was performed by SDS-
PAGE. Immunoblotting was performed with mAb45.1 
against conformational epitope I. Protein concentra-
tion was measured using either the BCA protein assay 
(Thermo Fisher Scientific) or by densitometric analysis of 
Coomassie stained SDS-PAGE gel using Image Quant TL 
(IQTL) software (GE Healthcare).
SEC–HPLC and RP‑HPLC analysis of R0.6C
Native size exclusion high-performance liquid chromatog-
raphy (SEC–HPLC) or reversed-phase HPLC (RP-HPLC) of 
intact R0.6C were performed using an Agilent 1100 Series 
HPLC System (Agilent Technologies, USA) equipped with 
a TSKgel G3000SWXL SEC column, 5 µm, 7.8 × 300 mm 
(Tosoh Bioscience, Japan) or equipped with a Vydac 
214TP C4 reversed-phase column, 5  µm, 4.6  ×  250  mm 
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(The Separations Group, CA, US), respectively. 210  pmol 
of protein was loaded on the SEC column and eluted with 
a 0.15  ml/min flow of elution buffer (200  mM phosphate, 
0.65 g/l l-arginine, 0.05%  NaN3, pH 6.7) at room tempera-
ture. For RP-HPLC, 210 pmol of protein was loaded on the 
RP-column and eluted with a linear gradient of 3–95% of 
0.1% trifluoroacetic acid (TFA), 20% isopropanol and 70% 
acetonitrile over 30 min. The absorbance was measured at 
280 or 215  nm for SEC–HPLC or RP-HPLC, respectively, 
and chromatographic peaks were integrated by HPLC 
ChemStation (Agilent Technologies, CA, US).
Mass spectrometry
Accurate molecular mass of full-length R0.6C was meas-
ured by LC–ESI–MS. 30 pmol of protein were loaded on 
a C4 pre-column (Acquity UPLC Protein BEH C4 Van-
guard, 1.7, 2.1 × 5 mm, Waters, USA) and eluted onto a 
Q-TOF mass spectrometer (Synapt G2 HDMS, Waters, 
UK) with a chromatographic gradient. LC–MS data 
where recorded and analyzed by MassLynx software 
(Waters, UK). Mass spectra were deconvoluted using 
the MaxEnt 1 algorithm in the MassLynx software. Pep-
tide mapping of R0.6C was performed by LC–MS/MS of 
tryptic digests. Guanidine hydrochloride, dithiothreitol 
and iodoacetamide were added to 100  pmol of protein. 
This was followed by addition of iodoacetamide and the 
protease trypsin. Tryptic peptides were desalted and 
chromatographically separated over 40 min on a UHPLC 
C18 pre column and column, respectively (Acquity UPLC 
BEH column, Waters, USA) using a nanoACQUITY 
UPLC system (Waters, USA). The eluate ionized by elec-
trospray ionization and data were acquired on the same 
mass spectrometer software as described above. LC–
MS/MS data were analyzed using PLGS (waters, USA) 
and peptide maps were created using DynamX (Waters, 
USA). Cysteine connectivity characterization was done 
with identical UPLC conditions as for peptide mapping. 
Tryptic digestion was additionally performed under simi-
lar conditions, with and without addition of guanidine 
hydrochloride, dithiothreitol or iodoacetamide to pro-
duce peptides without and without intact cysteine bonds, 
respectively. Collision induced dissociation (CID) frag-
mentation was performed on the two identified cross-
linked peptides to produce MS/MS spectra used for 
manual analyzing the MS/MS fragments by MassLynx 
software for characterization of cysteine connectivity.
Animals and immunogenicity studies
Female Wistar Hannover rats (Taconic, Denmark) and 
kept in the Laboratory Animal Facility Centre at Panum, 
University of Copenhagen, Denmark for 7  days before 
the first immunization. All procedures regarding animal 
immunizations complied with European and National 
regulations. Groups of eight rats were immunized by 
the s.c. route 3 times at 3-week intervals with increasing 
doses (2.5, 10, and 25 μg) of R0.6C. Protein preparations 
were emulsified in Montanide ISA720 VG (Seppic) imme-
diately before use. Responses were measured using sera 
taken three weeks after the third immunization (Day 63).
Enzyme‑linked immunosorbent assay (ELISA)
The mAb45.1 sandwich ELISA was performed as previ-
ously described [14, 15]. The coating concentration of 
recombinant Pfs48/45 (6C) and R0.6C was 0.5 µg/ml and 
bound antibodies were detected with HRP-conjugated 
rabbit-anti rat IgG-HRP (DAKO, Denmark) as described 
in detail [27]. The mAb45.1 competition ELISA was per-
formed as follows; Briefly, ELISA MaxiSorp microtitre 
plates  (Sterilin® ELISA plates, The Netherlands) were 
coated at 4  °C overnight with 100  µl per well of 5  µg/
ml of mAb45.1 in PBS pH 7.4. Wells were blocked with 
150 µl of 5% non-fat skimmed milk powder in PBS for 1 h 
followed by three washings with PBS containing 0.05% 
Tween 20 (PBST). Sera at threefold dilutions (50 µl) were 
mixed with 50 µl R0.6C (1 µg/ml) in PBST, added to the 
wells and incubated for 4 h at room temperature. Wells 
were washed with PBST and bound antigen was revealed 
with anti-His-HRP (1/6000 in PBST) for 2 h at room tem-
perature. Midpoint (EC50) values were calculated using 
GraphPad Prism 7, (GraphPad Software, USA).
Standard membrane feeding assay (SMFA)
The biological activity of anti-R0.6C antibodies was 
assessed in the SMFA as previously described in detail 
[15]. Estimates of transmission reducing activity (TRA) 
were generated using oocyst densities in individual mos-
quitoes, comparing test feeders with control feeders from 
the same experiment as described [33].
Statistical analysis
The Mann–Whitney rank sum test was used for analyz-
ing differences between groups. P < 0.05 was considered 
to be statistically significant.
Additional files
Additional file 1. Production and purification of R0.6C.
Additional file 2. Intact mass analysis of R0.6C. Mass spectra of full-
length antigens by LC–MS and peptide maps from LC–MS/MS of trypsin 
digested antigens. (a) Deconvoluted mass spectra of non-reduced R0.6C. 
(b) Deconvoluted mass spectra of reduced R0.6C. (c)Tryptic peptide maps 
of R0.6C. In brackets is the calculated accuracy of the measurement to the 
predicted mass in ppm. All measurements were done in duplicates.
Additional file 3. Stability of R0.6C. R0.6C was incubated at 4 °C for 0, 15 
and 30 days. Three and 1 µg of R0.6C with (+) and without (−) DTT was 
analyzed by (a) SDS-PAGE coomassie staining, (b) Immune-blotting using 
mAb 45.1 and (c) Sandwich ELISA. Antigens were captured with mAb45.1 
and detected with anti-His-HRP.
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